Systemic lupus erythematosus and Sjögren's syndrome

Editorial

George C Tsokos. Curr Opin Rheumatol. 2005 Sep.

. 2005 Sep;17(5):511-2.

doi: 10.1097/01.bor.0000174181.93030.59.

No abstract available

Comment on

Immune cells and cytokines in systemic lupus erythematosus: an update.
Kyttaris VC, Juang YT, Tsokos GC. Kyttaris VC, et al. Curr Opin Rheumatol. 2005 Sep;17(5):518-22. doi: 10.1097/01.bor.0000170479.01451.ab. Curr Opin Rheumatol. 2005. PMID: 16093827 Review.
Genetics of susceptibility and severity in systemic lupus erythematosus.
Croker JA, Kimberly RP. Croker JA, et al. Curr Opin Rheumatol. 2005 Sep;17(5):529-37. doi: 10.1097/01.bor.0000169360.15701.27. Curr Opin Rheumatol. 2005. PMID: 16093829 Review.
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.
Sfikakis PP, Boletis JN, Tsokos GC. Sfikakis PP, et al. Curr Opin Rheumatol. 2005 Sep;17(5):550-7. doi: 10.1097/01.bor.0000172798.26249.fc. Curr Opin Rheumatol. 2005. PMID: 16093832 Review.
Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy.
Hansen A, Lipsky PE, Dörner T. Hansen A, et al. Curr Opin Rheumatol. 2005 Sep;17(5):558-65. doi: 10.1097/01.bor.0000172801.56744.c3. Curr Opin Rheumatol. 2005. PMID: 16093833 Review.